Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Stephen Behrman"'
Autor:
Sheema Khan, Goutam Banerjee, Saini Setua, Daleniece Higgins Jones, Bhavin V. Chauhan, Anupam Dhasmana, Pratik Banerjee, Murali Mohan Yallapu, Stephen Behrman, Subhash C. Chauhan
Publikováno v:
Frontiers in Microbiology, Vol 14 (2023)
The composition of resident microbes in the human body is linked to various diseases and their treatment outcomes. Although studies have identified pancreatic ductal adenocarcinoma (PDAC)-associated bacterial communities in the oral and gut samples,
Externí odkaz:
https://doaj.org/article/756f6f10ec2a4e3996ac5e7bc153df8f
Autor:
Mehdi Chaib, Bilal B. Hafeez, Hassan Mandil, Deidre Daria, Ajeeth K. Pingili, Sonam Kumari, Mohammed Sikander, Vivek K. Kashyap, Guo-Yun Chen, Emmanuel Anning, Manish K. Tripathi, Sheema Khan, Stephen Behrman, Murali M. Yallapu, Meena Jaggi, Liza Makowski, Subhash C. Chauhan
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-15 (2022)
The probiotic-derived siderophore, ferrichrome, enhances anti-tumor immunity and improves the efficacy of checkpoint immunotherapy in a model of pancreatic cancer by repolarizing tumor-associated macrophages to a immunostimulatory M1 phenotype.
Externí odkaz:
https://doaj.org/article/f945b76f55ec4be9afc242551058f2f7
Autor:
Ana I. Bulnes, Orlando Garcia, Poornima Shaji, Swathi Holla, Nirnoy Dan, Anupam Dhasmana, Shabnam Malik, Murali Yallapu, Stephen Behrman, Subhash Chauhan, Sheema S. Khan
Publikováno v:
Cancer Research. 83:5493-5493
Introduction: Pancreatic Ductal Adenocarcinoma (PDAC) patients exhibit extremely poor prognosis. KRAS mutation on codon-12 is present in 70-95% of PDAC cases and it drives PDAC growth and progression. Galectin-1 (Gal-1) is present in both PDAC and st
Autor:
Ana I. Martinez Bulnes, Poornima Shaji, Nirnoy Dan, Melida Cantu, Shabnam Malik, Stephen Behrman, Swathi Holla, Murali Mohan Yallapu, Meena Jaggi, Subhash C. Chauhan, Sheema Khan
Publikováno v:
Cancer Research. 82:1038-1038
Introduction: In pancreatic ductal adenocarcinoma (PDAC), low patient survival rate remains a problem. The activating point mutation of KRAS on codon-12 is present in 70-95% of PDAC cases and so far, no success has been achieved to inhibit KRAS. KRAS
Autor:
Poornima Shaji, Ana Martinez, Melida Flores Cantu, Anupam Dhasmana, Neeraj Chauhan, Fnu Shabnam, Vincent Diego, Meena Jaggi, Stephen Behrman, Murali M. Yallapu, Subhash C. Chauhan, Sheema Khan
Publikováno v:
Cancer Research. 82:LB007-LB007
Background: Pancreatic cancer remains 3rd deadliest disease, with less than 7-10% survival rate. Little progress has been seen in patient’s outcome due to high desmoplasia and chemo-resistance. Immunotherapy has shown promising results in cancers,
Autor:
Mehdi Chaib, Bilal B. Hafeez, Hassan Mandil, Deidre Daria, Ajeeth K. Pingili, Sonam Kumari, Mohammed Sikander, Vivek K. Kashyap, Guo-Yun Chen, Emmanuel Anning, Manish K. Tripathi, Sheema Khan, Stephen Behrman, Murali M. Yallapu, Meena Jaggi, Liza Makowski, Subhash C. Chauhan
Publikováno v:
Communications biology. 5(1)
There is increasing evidence suggesting the role of microbiome alterations in relation to pancreatic adenocarcinoma and tumor immune functionality. However, molecular mechanisms of the interplay between microbiome signatures and/or their metabolites
Autor:
Stephen Behrman, Srilakshmi Narra, Mark H. Lyda, Matthew A. Dress, Thomas Callihan, Jignesh G. Parikh
Publikováno v:
Gastrointestinal Endoscopy. 80:341-342
Autor:
Brian M. Wolpin, J. Pablo Arnoletti, Wen Wee Ma, Brian G. Czito, Al B. Benson, Edgar Ben-Josef, Andrew H. Ko, John P. Hoffman, Stephen Behrman, Robert A. Wolff, Sean J. Mulvihill, Dorothy A. Shead, Peter Muscarella, Samuel Whiting, Nipun B. Merchant, Albert C. Koong, William G. Hawkins, Jorge Obando, Martha B. Pitman, Aaron R. Sasson, Anitra Tally, Ephraim S. Casper, Margaret A. Tempero, Deborah A. Freedman-Cass, Sarah P. Thayer, Mokenge P. Malafa, Steven J. Cohen, Joshua D. I. Ellenhorn, Srinadh Komanduri, Eric K. Nakakura, Joseph M. Herman
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab394188be44ed56571b502dfe74a307
http://www.scopus.com/inward/record.url?eid=2-s2.0-84863206071&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-84863206071&partnerID=MN8TOARS
Autor:
Margaret A. Tempero, Aaron R. Sasson, Peter Muscarella, Robert A. Wolff, Edgar Ben-Josef, Joshua D.I. Ellenhorn, Jordan D. Berlin, John L. Cameron, Robert S. Warren, Ephraim S. Casper, Christopher G. Willett, Al B. Benson, John P. Hoffman, Michelle Duff, William G. Hawkins, Douglas S. Tyler, Samuel Whiting, Stephen Behrman, J. Pablo Arnoletti, Steven J. Cohen, Boris W. Kuvshinoff, Mokenge P. Malafa, Eric K. Nakakura, Sarah P. Thayer
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
In the year 2005, an estimated 31,800 people will die of pancreatic cancer in the United States. This disease is the fourth most common cause of cancer-related death among men in the United States. Its peak incidence occurs in the seventh and eighth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd0d5fcae31b5160499a808bf20ef8c
http://www.scopus.com/inward/record.url?eid=2-s2.0-33644690815&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-33644690815&partnerID=MN8TOARS